Technology, Market, and Team.

Technology: We have identified a unique Biomarker for Triple Negative Breast Cancer and intend to further develop our highly differentiated anti-breast cancer therapies. We believe these therapies will also be effective for all kinds of Breast cancers. We hold 4 US patents for our technology and a PCT patent is pending. We are currently focused on the R & D of our custom Small Molecule Entities that we identified in-house. 

Market: The Global Anti-Breast Cancer market is expected to reach $18.2 billion by 2023 and we envisage capturing at least 5% of this market.

Team: Exceptionally qualified team of Scientists, Clinicians, Management team and Advisors with collective experience of over 80 years